Results 61 to 70 of about 2,348 (179)

The Contribution to the Assignment of Defined Daily Dose (DDD) to Antineoplastic Drugs of the Italian Working Group on DDD

Pharmacoepidemiology and Drug Safety, Volume 35, Issue 5, May 2026.
ABSTRACT Purpose To report the experience of the Italian Working Group on DDD (Ita‐DDD‐wg) in assigning DDDs to a list of antineoplastic agents. Methods Active substances from the ATC L01 group with no assigned DDD and reimbursed at least once during 2021 by the Italian Healthcare Service were identified.
Angela Boccia, Giulia Hyeraci, Anna Girardi, Rosa Gini, Gianluca Trifirò, Ylenia Ingrasciotta, Andrea Spini, Valentina Ientile, Elisabetta Poluzzi, Giampiero Mazzaglia, Ippazio Cosimo Antonazzo, Casula Manuela, Elena Tragni, Olivia Leoni, Arianna Mazzone, Michele Ercolanoni, Martina Zanforlini, Ursula Kirchmayer, Belleudi Valeria, Marco Finocchietti, Francesco Barone‐Adesi, Giuseppe Roberto   +21 more
wiley   +1 more source

26 | Tumor size may predict early response to sonidegib in locally-advanced basal cell carcinoma: clinical and histopathological correlates from a monocentric case series

Dermatology Reports
Background: Sonic Hedgehog (SHH) inhibitors, including sonidegib, have emerged as effective therapies for locally advanced basal cell carcinoma (LA-BCC). However, variability in clinical response has been observed.
Italian Melanoma Intergroup
doaj   +1 more source

Hedgehog inhibitor sonidegib potentiates 177Lu-octreotate therapy of GOT1 human small intestine neuroendocrine tumors in nude mice

BMC Cancer, 2017
Background 177Lu-octreotate can be used to treat somatostatin receptor expressing neuroendocrine tumors. It is highly effective in animal models, but clinical studies have so far only demonstrated low cure rates.
Johan Spetz, Britta Langen, Nils Rudqvist, Toshima Z. Parris, Khalil Helou, Ola Nilsson, Eva Forssell-Aronsson   +6 more
doaj   +1 more source

Cancer‐Associated Fibroblasts Functions as Multifunctional Architects of the Tumor Stroma and Represent Emerging Therapeutic Vulnerabilities

Advanced Science, Volume 13, Issue 24, 27 April 2026.
ABSTRACT Cancer‐associated fibroblasts (CAFs) are the predominant stromal components within the tumor microenvironment (TME), playing multifaceted roles in cancer progression through dynamic interactions with neoplastic and immune cells. Emerging evidence has revealed remarkable heterogeneity and plasticity of CAFs, which originate from diverse ...
Rujiao Liu, Lili Su, Shuiping Gao, Wenting Liu, Hongxia Wang   +4 more
wiley   +1 more source

Metastatic Basal Cell Carcinoma With Unusual Molecular Genetics Findings

Clinical Case Reports, Volume 14, Issue 4, April 2026.
ABSTRACT Basal cell carcinoma (BCC) rarely metastasizes to other parts of the body. When metastasis occurs, it usually involves regional lymph nodes. BCC lesions located in the head and neck region have been shown to spread to cervical lymph nodes.
Noora Al‐Hail, Majid Al‐Abdulla, Syed Rizvi, Nazeeha Al‐Hayki   +3 more
wiley   +1 more source

Efficacy and safety of sonidegib combined with photodynamic therapy in basal cell carcinoma: A retrospective case series of 7 patients

Photodiagnosis and Photodynamic Therapy
Background: Management of basal cell carcinoma (BCC) in cosmetically critical facial areas remains challenging when surgery is contraindicated or declined.
Jiaxi Lai, Kaixin Li, Min Xu, Liyuan Zeng, Caiyan Li, Siqi Li, Li Zhong, Wei Liu, Xiaoshuang Liang, Jingwen Zou, Renliang He, Weiqin Shen, Min Li, Yongfeng Chen, Rongyi Chen   +14 more
doaj   +1 more source

Pleural‐Based GLI1‐Altered Mesenchymal Tumor With ACTB‐GLI1 Fusion: A Rare Pulmonary Entity Mimicking Synovial Sarcoma

Thoracic Cancer, Volume 17, Issue 7, April 2026.
Pleural‐based GLI1‐altered mesenchymal tumor presenting as an incidental thoracic mass, characterized by biphasic morphology and ACTB‐GLI1 fusion, managed by thoracoscopic resection and surveillance. ABSTRACT GLI1‐altered mesenchymal tumors are exceptionally rare mesenchymal tumors, with recent molecular studies implicating GLI1 gene fusion or ...
Marco Lizwan, Li Xiao, Chun Yuen Chow, Hiu Yeung Lau, Boon‐Hean Ong   +4 more
wiley   +1 more source

A physiologically-based pharmacokinetic modeling approach to predict drug-drug interactions of sonidegib (LDE225) with perpetrators of CYP3A in cancer patients

, 2017
Sonidegib (Odomzo®) is an orally available Smoothened inhibitor for the treatment of advanced basal cell carcinoma. Sonidegib was found to be metabolized primarily by cytochrome P450 (CYP)3A in vitro.
Rebello, Sam, Won, Christina, Einolf, Heidi, Zhou, Jocelyn, Wang, Lai   +4 more
core   +1 more source

RNA‐Sequencing Reveals Two Subgroups of Eccrine Porocarcinomas and Poromas

Journal of Cellular and Molecular Medicine, Volume 30, Issue 8, April 2026.
ABSTRACT Eccrine porocarcinoma (EPC), a rare malignant eccrine gland tumour, remains molecularly understudied. Transcriptomic studies of EPC and benign eccrine poroma (EP) have identified recurrent fusions and expression changes, but differences distinguishing malignant EPC from benign EP are unclear.
Maya Puttonen, Sami Kilpinen, Maria von Willebrand, Kalle Ojala, Tom Böhling, Virve Koljonen, Harri Sihto   +6 more
wiley   +1 more source

Bone Metastasis: Molecular Mechanisms, Clinical Management, and Therapeutic Targets

MedComm, Volume 7, Issue 2, February 2026.
This figure emphasizes current understanding of the regulatory networks, approach of diagnose, available preclinical models and clinical management of bone metastasis. to guide future therapeutic development. A deep understanding of these aspects enables the prevention of bone metastasis and the implementation of effective therapeutic strategies ...
Jingyuan Wen, Binghua Li, Shengjia Wang, Yongzhong Yao, Zhao Huang, Decai Yu   +5 more
wiley   +1 more source